Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis.

ABSTRACT:

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by increased mortality associated with cardiometabolic disorders including dyslipidaemia, insulin resistance, and cachectic obesity. Tumour necrosis factor inhibitors and interleukin 6 receptor blocker licensed for the treatment of RA decrease inflammation and could thus improve cardiovascular risk, but their effects on body composition and metabolic profile need to be clarified. We investigated the effects of tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, on body composition and metabolic profile in patients treated for RA.

Methods

Twenty-one active RA patients treated with TCZ were included in a 1 year open follow-up study. Waist circumference, body mass index, blood

SUBMITTER: Tournadre A 

PROVIDER: S-EPMC5566648 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature